COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study: MIDAS Study (MIDAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01961375
Recruitment Status : Active, not recruiting
First Posted : October 11, 2013
Last Update Posted : September 14, 2020
Information provided by (Responsible Party):

Brief Summary:
The study is designed as non interventional to observe the continuation rate and the patient satisfaction in women who have a LNG-IUS (Levonorgestrel releasing Intrauterine system) inserted for contraception over the period of 12 months under real life condition in India.The study will begin after the study approval by ethics committee.All Indian women aged between 18-49 years who are initiating LNG IUS therapy for contraception will be included in study after taking the informed consent.Patients will be observed for upto 12 months.The study involves general examination of patients, collection of data like medical history, previous contraceptive use,concomitant medication etc.The study is planned to enroll 600 subjects from multiple study centers spread across India. The study data will be analyzed with appropriate statistical methods.

Condition or disease Intervention/treatment
Contraception Drug: Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)

Layout table for study information
Study Type : Observational
Actual Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study.
Actual Study Start Date : October 30, 2015
Actual Primary Completion Date : November 28, 2018
Estimated Study Completion Date : March 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birth Control

Group/Cohort Intervention/treatment
Group 1
BAY 86-5028; Levonorgestrel- Intra Uterine System
Drug: Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)
Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion

Primary Outcome Measures :
  1. Percentage continuation rate of LNG IUS at end of observation period. [ Time Frame: 12 months ]
  2. Percentage of Women with user satisfaction scoring somewhat satisfied to very satisfied [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Cumulative discontinuation rate for pregnancy [ Time Frame: 12 months ]
  2. Cumulative discontinuation rate for other medical reasons [ Time Frame: 12 months ]
  3. Cumulative discontinuation rate for non-medical reasons [ Time Frame: 12 months ]
  4. Mean percentage of women with amenorrhea [ Time Frame: 12 months ]
  5. Mean percent of women with spotting, inter-menstrual bleeding [ Time Frame: 12 months ]
  6. Distribution of contraceptive usage patterns [ Time Frame: 12 months ]
    contraceptive usage patterns included:birth-spacing, long term contraception, postpartum contraception, post-abortion contraception, switch from other method, contraception for other medical reasons like heart disease, etc

  7. Incidence rate of drug-related adverse events [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The study subjects will be enrolled from multiple sites like women's hospitals, tertiary care institutes, Family planning clinics and gynaecological consulting centres.

Inclusion Criteria:

  • Subject aged between 18-49 years who are initiating LNG IUS therapy for contraception.
  • Subject willing to provide informed consent and comply with study procedure.

Exclusion Criteria:

  • Exclusion criteria must be read in conjunction with the local product information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01961375

Layout table for location information
Multiple Locations, India
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01961375    
Other Study ID Numbers: 16199
MA1210IN ( Other Identifier: company internal )
First Posted: October 11, 2013    Key Record Dates
Last Update Posted: September 14, 2020
Last Verified: September 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral